NuWays reiterates Buy on Pentixapharm, sets EUR 7.2 price target

Reuters2026/07/31 07:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NuWays reiterated a BUY rating on Pentixapharm, setting a 12-month target price of EUR 7.2.
Report flagged a completed capital increase of about 11,000,000 new shares at EUR 1.85, raising about EUR 19.7 million net.
Pro forma cash seen at about EUR 25 million, extending runway from Q1 2027 into early 2028, funding initial Phase 3 execution.
NuWays expects first patient in for the PANDA Phase 3 PentixaFor study in H2 2026, with topline data targeted for 2028.
Commercial partnering seen as likely in 2027, with talks under way, supported by improved negotiating leverage from the larger cash position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26346) on July 31, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NuWays reiterates Buy on Pentixapharm, sets EUR 7.2 price target

You may also like

Crypto prices